We are a clinical-stage biotech company pioneering novel therapies for hematologic cancers and diseases linked to clonal hematopoiesis (CH)—a key driver of immune aging.

Our lead program, granted Orphan Drug Designation by the Korean Ministry of Food and Drug Safety, is currently undergoing a pivotal clinical trial in Korea.

We are driven by a sense of urgency and purpose to translate cutting-edge science into transformative treatments—bringing new hope to patients with limited options.

For more information, please visit our website.

- Official Website: https://en.nobomedicine.com/

NOBO Medicine

Org chart

Teams

Offices